Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

33%

3 of 9 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

6(66.7%)

Phase 4

3(33.3%)

9Total

Phase 1(6)

Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05721235Phase 4Completed

A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

Role: lead

NCT06000501Phase 4Completed

Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening

Role: collaborator

NCT05685732Phase 4Completed

An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

Role: lead

NCT04617782Phase 1Completed

Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers

Role: lead

NCT03397862Phase 1Completed

A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

Role: lead

NCT03438604Phase 1Completed

A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)

Role: lead

NCT03432195Phase 1Completed

A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations

Role: lead

NCT02968719Phase 1Completed

A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®

Role: lead

NCT03259958Phase 1Completed

A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®

Role: lead

All 9 trials loaded